Replies to post #242805 on Biotech Values

[DewDiligence]

FIXX reverse-merges with—(private)—Q32 Bio Inc:

https://www.globenewswire.com/news-release/2023/11/16/2781720/0/en/Q32-Bio-and-Homology-Medicines-Announce-Merger-Agreement.html

The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

…Pre-merger Homology Medicines stockholders are expected to own approximately 25% of the combined company and pre-merger Q32 Bio stockholders (including those purchasing Q32 Bio shares in the concurrent private financing discussed above) are expected to own approximately 75%...

…Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.

FIXX has been in the penalty box since the FDA put a clinical hold on its lead program in 2022 (#msg-167944477), despite an updated protocol for the trial in question (#msg-169133433).